Co-Diagnostics shares surge as investors react to Ebola-test development update and outbreak headlines

By: Quiver PriceTracker

Posted: 1 day, 22 hours ago / May 26, 2026 5:36 p.m. UTC

CODX

Co-Diagnostics, Inc. (CODX) is up 89.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to company news around advancing an Ebola (Bundibugyo virus) PCR assay development strategy amid heightened attention on a Bundibugyo-related outbreak. With CODX’s small market capitalization and historically high volatility, the rally may have been amplified by momentum trading and short covering.

Details:

The company announced it advanced its PCR assay development strategy targeting Bundibugyo virus (BDBV), describing the work as part of its outbreak-response preparedness efforts and supported by its joint venture operations.

The update follows public-health alerts describing a Bundibugyo virus Ebola outbreak in parts of the Democratic Republic of the Congo and Uganda, which can increase investor focus on diagnostics developers.

Trading volume spiked alongside the price move, suggesting the catalyst may have triggered a rapid re-rating by short-term traders rather than a fundamental change in near-term revenue.

This could also be a “low-float” style squeeze dynamic: when a small stock gets a headline-driven narrative, incremental buying can push the price sharply higher.

Sources:

PR Newswire, Investing.com, CDC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CODX Hedge Fund Activity

We have seen 7 institutional investors add shares of $CODX stock to their portfolio, and 28 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RENAISSANCE TECHNOLOGIES LLC removed 24,344 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $45,279
GEODE CAPITAL MANAGEMENT, LLC removed 14,971 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $27,846
BLACKROCK, INC. removed 14,248 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $26,501
JANE STREET GROUP, LLC removed 8,031 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $14,937
VANGUARD GROUP INC added 6,772 shares (+11.9%) to their portfolio in Q4 2025, for an estimated $34,252
UBS GROUP AG added 6,320 shares (+603.1%) to their portfolio in Q1 2026, for an estimated $11,755
HRT FINANCIAL LP removed 4,976 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,168

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.